NCT07013760Completed
Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain
Observational Retrospective Study to Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain
Source: ClinicalTrials.gov · Last updated 12 Jan 2026
Brief summary (registry, in English)
Observational retrospective study to characterize and assess clinical outcomes of patients receiving tezepelumab after marketing approval in Spain
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 420 (actual)
- First submitted
- 4 Apr 2025
- Start date
- 23 Jun 2025
- Primary completion date
- 19 Dec 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT07013760
What you commit to
- Study type: Observational
- Participants enrolled: 420
- From 23 Jun 2025 to the primary completion date, 19 Dec 2025
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received tezepelumab or any biologic drug for the treatment of asthma in a clinical trial at any time during the 12-months prior to the index date\*.
- Patients who had initiated 3 or more non-tezepelumab biologic treatment (omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab) for severe asthma at any time prior to the index date).
Who the study is looking for
- Patients who received at least 1 tezepelumab dose after commercialization in Spain diagnosed with severe asthma who are inadequately controlled with high-dose inhaled corticosteroids and a long-acting β2-agonist ± additional medications for asthma control.
- Patients aged ≥12 years at the index date.
- Patients with continuous enrolment in the data source for at least 12-months before the index date.
- Patients with at least three months of continuous enrolment in the data source after the index date.
Age in the registry: 12 years to 105 years · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Andalucia | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Cantabria | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Castilla La Mancha | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Cataluna | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | C. Valenciana | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | C. Y Leon | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Extremadura | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Galicia | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Islas Canarias | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Navarra | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Pais Vasco | Spain | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.